Skip to main content
Ross Donehower, MD, Oncology, Baltimore, MD, Johns Hopkins Hospital

RossCDonehowerMD

Oncology • Baltimore, MD

Professor of Oncology, Professor of Medicine, Johns Hopkins University School of Medicine; Director, Medical Oncology/Hematogy Fellowship Training Program, Director, Division of Medical Oncology

Join to view full profile

Dr. Donehower is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Donehower's full profile

Already have an account?

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Medical Oncology, 1980
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 1974 - 1976
  • University of Minnesota Medical School
    University of Minnesota Medical SchoolClass of 1974

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1979 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Excellence in Teaching Award American Society of Clinical Oncology, 2017
  • America's Top Doctors Castle Connolly, 2002-2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Johns Hopkins University Hematology Oncology Fellowship
    Johns Hopkins University Hematology Oncology FellowshipApril 30th, 2017

Grant Support

  • Clinical Oncology Research Career Development ProgramNational Cancer Institute1997–2007
  • Phase I Trial/Pharmacokinetis Of Tas 103 Solid In TumorsNational Center For Research Resources2000–2002
  • Trial Of Bryostatin 1 Given As Continuous Infusion In Cancer PatientsNational Center For Research Resources1998–2002
  • Phase I Dose Escalation, Safety, Tolerability Of Tas 103National Center For Research Resources1997–2002
  • Phase I Trials Of Anticancer AgentsNational Cancer Institute1998–2000
  • Phase II Pharm Study--Flavopiradol (Nsc 649890) In Colorectal CancerNational Center For Research Resources1999
  • Phase II Trials Of New Anticancer AgentsNational Cancer Institute1994–1998
  • Phase I Clinical Trial Of Anticancer AgentsNational Cancer Institute1995–1997
  • Pharmacokinetic Studies Of Anticancer AgentstheDivision Of Cancer Treatment1994–1995
  • Navelbine Bioavailability In Solid Tumors And LymphomaNational Center For Research Resources1992–1993
  • 7u85 Mesylate Intravenous Administration Daily For Five DaysNational Center For Research Resources1992–1993
  • Phase I And Pharmacokinetic Studies Of Anticancer AgentsDivision Of Cancer Treatment1990–1993
  • Bioavailability Of Piritrexim Isethionate In Advanced Cancer PatientsNational Center For Research Resources1992

Professional Memberships

Hospital Affiliations

External Links

Dr. Ross Donehower, Dr. Ross Donehower, MD, Dr. R Donehower, Dr. Ross C Donehower